Last updated: September 14, 2026
Zegalogue autoinjector is Zealand Pharma’s ready-to-use dasiglucagon rescue product for severe hypoglycemia in adults and children aged 6 years and older with diabetes. The product competes in a growing glucagon rescue market against Gvoke HypoPen from Xeris Biopharma, Baqsimi nasal glucagon from Eli Lilly and traditional emergency glucagon kits. Zealand has expanded access through pharmacies, insurance coverage, savings programs, and institutional channels, but the product remains exposed to high launch costs, reimbursement friction, and competition from established alternatives.
Public company reporting does not separately disclose revenue for the Zegalogue autoinjector versus the prefilled syringe. Zealand reports product revenue at the Zegalogue or dasiglucagon-product level, which limits precise assessment of autoinjector-specific sales.
What is Zegalogue autoinjector and how does it work?
Zegalogue is a single-dose, 0.6 mg dasiglucagon injection supplied in an autoinjector and prefilled syringe. Dasiglucagon is a glucagon analog that increases blood glucose by stimulating hepatic glycogen breakdown and glucose release.
The autoinjector is designed for non-healthcare-professional use during severe hypoglycemia. It removes the reconstitution step required by older emergency glucagon kits. The device is administered subcutaneously and is intended for use when a patient is unable to consume carbohydrates orally.
| Product characteristic |
Zegalogue autoinjector |
| Active ingredient |
Dasiglucagon |
| Dose |
0.6 mg |
| Route |
Subcutaneous |
| Indication |
Severe hypoglycemia |
| Approved population |
Adults and children aged 6 years and older |
| FDA approval |
March 22, 2021 |
| Manufacturer |
Zealand Pharma |
| Primary market |
United States |
| Device |
Single-dose autoinjector |
| Alternative presentation |
Single-dose prefilled syringe |
The FDA approved Zegalogue based on trials showing rapid glucose recovery in adults and pediatric patients with type 1 diabetes. The commercial value proposition is ease of administration relative to conventional glucagon emergency kits, which require mixing a powder and liquid before injection. (U.S. Food and Drug Administration, 2021a, 2021b)
How large is the market for ready-to-use glucagon?
The ready-to-use glucagon market has expanded because diabetes organizations have increased emphasis on emergency preparedness, schools and workplaces have gained greater access to rescue products, and caregivers prefer products that do not require reconstitution.
The principal commercial segments are:
- Prescription rescue products for people with type 1 diabetes.
- Caregiver and household emergency kits.
- School, university, employer, and public-access programs.
- Hospital and institutional emergency stock.
- Insurance-covered pharmacy dispensing.
Zegalogue competes in the same convenience-driven category as Gvoke HypoPen and Baqsimi. The products differ in delivery system:
| Product |
Company |
Delivery system |
Main commercial advantage |
| Zegalogue |
Zealand Pharma |
Autoinjector and prefilled syringe |
Familiar injection format and stable liquid formulation |
| Gvoke HypoPen |
Xeris Biopharma |
Autoinjector |
Ready-to-use subcutaneous delivery |
| Baqsimi |
Eli Lilly |
Nasal powder |
Needle-free administration |
| Traditional glucagon kits |
Multiple manufacturers |
Reconstituted injection |
Lower-cost, established emergency option |
The market is commercially attractive but relatively concentrated. Product differentiation depends less on pharmacology than on device usability, caregiver confidence, formulary status, pricing, patient support, and availability during an emergency.
What has been the financial trajectory for Zegalogue?
Zealand has not publicly reported a separate revenue line for the autoinjector. Its disclosures generally combine Zegalogue-related product revenue or report product sales at a level that does not isolate device presentation, geography, channel, or payer.
The financial trajectory has four identifiable phases:
2021 launch phase
Zegalogue launched in the United States after FDA approval in 2021. Early commercial spending focused on field access, payer contracting, patient support, specialty and retail distribution, and physician awareness. Initial sales were constrained by the need to establish formulary coverage and persuade prescribers to move away from older kits and competing ready-to-use products.
2022 access-building phase
The product moved from launch stocking toward recurring prescription demand. Zealand expanded commercial programs and emphasized the autoinjector’s simplified administration. Revenue growth depended heavily on reimbursement rather than on new clinical indications.
2023 scale-up phase
The commercial opportunity shifted toward increasing prescription volume, improving refill behavior, and gaining institutional adoption. Zegalogue remained a product-revenue contributor for Zealand, but the company’s financial profile continued to be dominated by pipeline assets, licensing transactions, and research spending rather than by Zegalogue alone.
2024 onward
Zegalogue’s growth potential depends on three factors:
- Expansion of covered lives and favorable formulary placement.
- Greater adoption of emergency glucagon among patients with intensive insulin therapy.
- Increased institutional and public-access purchasing.
The product’s earnings contribution is limited by the scale of the severe-hypoglycemia population, competition from Baqsimi and Gvoke, and the possibility that payers prefer lower-cost generic or traditional glucagon kits.
How does Zegalogue compare with Gvoke and Baqsimi?
Zegalogue versus Gvoke HypoPen
Zegalogue and Gvoke are direct device competitors because both use ready-to-administer subcutaneous delivery. Their commercial competition is likely to be decided by:
- Payer formulary position.
- Patient copay.
- Pharmacy availability.
- Caregiver training.
- Device reliability and ease of use.
- Manufacturer support programs.
Gvoke has an earlier commercial position in the ready-to-use injectable category. Zegalogue’s differentiation is based on dasiglucagon chemistry, product design, and Zealand’s focus on diabetes rescue applications.
Zegalogue versus Baqsimi
Baqsimi eliminates needles and may be preferred by caregivers who are uncomfortable with injections. Its principal limitation is that nasal delivery can be affected by nasal congestion or administration circumstances. Zegalogue provides a conventional injection route with a device designed for rapid subcutaneous use.
Baqsimi has the benefit of Eli Lilly’s larger commercial infrastructure and established diabetes franchise. Zealand is more dependent on Zegalogue-specific execution and partnerships.
Zegalogue versus traditional glucagon kits
Traditional kits generally have a lower acquisition cost but are harder to administer. Their preparation requirements create a practical disadvantage during emergencies. They remain relevant where payers, hospitals, schools, or patients prioritize price over convenience.
What is the FDA regulatory status of Zegalogue?
Zegalogue is FDA-approved for the treatment of severe hypoglycemia in adults and children aged 6 years and older with diabetes. The approval covers the autoinjector and prefilled syringe presentations.
The product is not a biologic and therefore does not face a biosimilar pathway. Competitive entry would occur through the drug approval and patent-certification framework applicable to small-molecule products, including an abbreviated new drug application where a qualifying generic product can demonstrate pharmaceutical equivalence and bioequivalence.
The FDA-approved label identifies key risks including nausea, vomiting, headache, injection-site reactions, and hypokalemia. Zegalogue is contraindicated in patients with pheochromocytoma or insulinoma. (U.S. Food and Drug Administration, 2021b)
What patents protect Zegalogue autoinjector?
Protection for Zegalogue can arise from several patent categories:
- Dasiglucagon composition-of-matter patents.
- Stable liquid glucagon-analog formulations.
- Pharmaceutical compositions and pH-control systems.
- Manufacturing and purification methods.
- Autoinjector or container-closure technology.
- Methods of treating severe hypoglycemia.
The most commercially relevant protection is likely to be formulation and active-ingredient protection rather than the generic concept of an autoinjector. Device patents can matter, but a competing manufacturer may design around a delivery-device claim while retaining a similar clinical presentation.
A current Orange Book review is required to determine the active listed patents, expiration dates, pediatric exclusivity, and any patent-term adjustment. Public company statements and FDA labeling do not establish a complete patent-expiration schedule for every Zegalogue presentation.
When does Zegalogue lose exclusivity?
Zegalogue’s regulatory exclusivity and patent exclusivity are separate.
FDA exclusivity generally depends on the approval pathway and does not necessarily prevent all competitive products after patent expiry. Patent protection may extend beyond regulatory exclusivity if composition, formulation, or method-of-use patents remain enforceable.
Potential generic entry would require:
- An ANDA or other qualifying FDA application.
- Certification against listed patents.
- Resolution of any Paragraph IV litigation.
- Approval of a product that matches the reference product’s relevant dosage form and strength.
- Commercial access to the device or an approved equivalent delivery presentation.
There is no biosimilar risk because dasiglucagon is a synthetic peptide drug, not an FDA-licensed biologic reference product.
Which companies are challenging Zegalogue commercially?
The main competitive threats are commercial rather than litigation-driven:
| Company |
Product |
Threat to Zegalogue |
| Xeris Biopharma |
Gvoke HypoPen |
Direct ready-to-use injectable competitor |
| Eli Lilly |
Baqsimi |
Needle-free rescue alternative and stronger diabetes infrastructure |
| Generic manufacturers |
Traditional glucagon products |
Lower-price substitution |
| Device and formulation developers |
Future liquid or nasal glucagon products |
Potential convenience and pricing pressure |
No broad public record establishes a major Paragraph IV litigation campaign targeting Zegalogue’s autoinjector as of the latest publicly available company and FDA materials reviewed for this analysis.
What generic launch risks exist?
Generic risk is likely to emerge in stages rather than through a single event.
First, traditional glucagon kits can pressure Zegalogue pricing without being direct device substitutes. Second, a generic or alternative liquid glucagon product could compete on price if it obtains an FDA-approved presentation with comparable clinical use. Third, a competing ready-to-use autoinjector could target the same patient and caregiver segment while designing around Zealand’s device claims.
The highest-value protection is therefore the combination of active ingredient, stable formulation, delivery system, and approved labeling. Weakness in any one layer may not eliminate market exclusivity, but it can reduce pricing power.
What licensing deals affect Zegalogue?
Zegalogue is primarily associated with Zealand Pharma rather than a large pharmaceutical commercialization partner. Zealand has used partnerships for other pipeline programs, but Zegalogue’s commercial trajectory has been driven by Zealand’s own U.S. strategy.
The absence of a major global partner gives Zealand control over pricing, positioning, and commercial execution. It also leaves Zealand responsible for sales infrastructure, market-access costs, inventory management, and post-launch promotion.
How strong is the Zegalogue commercial position?
Zegalogue has a credible product profile but a limited competitive moat.
| Factor |
Assessment |
| Clinical utility |
Strong for emergency severe hypoglycemia |
| Administration convenience |
Strong relative to reconstituted glucagon |
| Device differentiation |
Moderate; Gvoke is a direct competitor |
| Brand scale |
Weaker than Eli Lilly’s diabetes infrastructure |
| Pricing power |
Moderate to weak under payer pressure |
| Regulatory position |
Established FDA approval |
| Biosimilar exposure |
None |
| Generic exposure |
Dependent on formulation and patent barriers |
| Revenue visibility |
Limited by non-disclosure of autoinjector-specific sales |
| Commercial upside |
Dependent on payer access and institutional adoption |
Key Takeaways
- Zegalogue autoinjector is a 0.6 mg ready-to-use dasiglucagon product approved by the FDA in 2021.
- Its direct injectable competitor is Gvoke HypoPen; Baqsimi competes through needle-free nasal delivery.
- Zealand does not publicly separate autoinjector revenue from other Zegalogue presentations.
- Financial performance depends on prescriptions, payer coverage, institutional purchasing, and patient-support programs.
- Zegalogue is a small-molecule drug and has no biosimilar pathway.
- Generic risk will depend on active-ingredient, formulation, method-of-use, and device patent protection.
- The product’s commercial moat is based on convenience and access rather than a clearly dominant delivery technology.
- Eli Lilly has a structural commercial advantage through Baqsimi and its broader diabetes infrastructure.
- The key investment issue is whether Zealand can grow recurring Zegalogue demand without excessive pricing concessions and commercial spending.
FAQs About Zegalogue Autoinjector
Is Zegalogue the same as glucagon?
No. Zegalogue contains dasiglucagon, a glucagon analog engineered for a stable liquid formulation. Traditional glucagon rescue products generally require reconstitution before injection.
Can Zegalogue autoinjector be used in children?
Yes. FDA labeling covers adults and children aged 6 years and older with diabetes who require treatment for severe hypoglycemia.
Does Zegalogue have biosimilar competition?
No. Zegalogue is not a biologic reference product, so biosimilar competition does not apply. Potential competition would involve generic or other glucagon products.
Is Zegalogue covered by insurance?
Coverage varies by insurer, formulary tier, deductible, prior authorization, and patient-support eligibility. Commercial access can differ materially between employer plans, Medicaid programs, and Medicare-related coverage.
What is the biggest commercial risk for Zegalogue?
The largest risk is substitution by competing ready-to-use or needle-free glucagon products, combined with payer pressure that forces lower net pricing. Zegalogue-specific revenue is also difficult to evaluate because Zealand does not separately disclose autoinjector sales.
References
-
U.S. Food and Drug Administration. (2021a, March 22). FDA approves first ready-to-use glucagon treatment for severe hypoglycemia. https://www.fda.gov/news-events/press-announcements/fda-approves-first-ready-use-glucagon-treatment-severe-hypoglycemia
-
U.S. Food and Drug Administration. (2021b). Zegalogue (dasiglucagon) injection prescribing information. Zealand Pharma A/S.
-
Zealand Pharma A/S. (2022). Annual report 2021. Copenhagen, Denmark: Zealand Pharma A/S.
-
Zealand Pharma A/S. (2023). Annual report 2022. Copenhagen, Denmark: Zealand Pharma A/S.
-
Zealand Pharma A/S. (2024). Annual report 2023. Copenhagen, Denmark: Zealand Pharma A/S.
-
Xeris Biopharma Holdings, Inc. (2024). Annual report on Form 10-K for fiscal year 2023. U.S. Securities and Exchange Commission.
-
Eli Lilly and Company. (2024). Annual report on Form 10-K for fiscal year 2023. U.S. Securities and Exchange Commission.
-patent-expirations.png "ZEGALOGUE (AUTOINJECTOR) drug patent expirations")
